<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Pharma — Januar 2022]]></title><description><![CDATA[<p dir="auto">Could AstraZeneca Help You Retire a<br />
Millionaire? <a href="https://www.proinvestor.com/investornyt/757873/could-astrazeneca-help-you-retire-a-millionaire" rel="nofollow ugc">https://www.proinvestor.com/investornyt/757873/could-astrazeneca-help-you-retire-a-millionaire</a></p>
]]></description><link>https://dev.proinvestor.com/forum/topic/400858/pharma-januar-2022</link><generator>RSS for Node</generator><lastBuildDate>Sun, 07 Jun 2026 11:20:06 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/400858.rss" rel="self" type="application/rss+xml"/><pubDate>Sat, 01 Jan 2022 11:24:03 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Pharma — Januar 2022 on Mon, 31 Jan 2022 07:44:37 GMT]]></title><description><![CDATA[<p dir="auto">Sanofi: CHMP Recommends Approval Of Dupixent For Children With Severe Asthma With Type2 Inflammation <a href="https://www.proinvestor.com/investornyt/773492/sanofi-chmp-recommends-approval-of-dupixent-for-children-with-severe-asthma-with-type2-inflammation" rel="nofollow ugc">https://www.proinvestor.com/investornyt/773492/sanofi-chmp-recommends-approval-of-dupixent-for-children-with-severe-asthma-with-type2-inflammation</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037536</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037536</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Mon, 31 Jan 2022 07:44:37 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Mon, 31 Jan 2022 07:42:18 GMT]]></title><description><![CDATA[<p dir="auto">Roche: FDA Approves Vabysmo To Treat Two Vision-threatening Retinal Conditions <a href="https://www.proinvestor.com/investornyt/773501/roche-fda-approves-vabysmo-to-treat-two-vision-threatening-retinal-conditions" rel="nofollow ugc">https://www.proinvestor.com/investornyt/773501/roche-fda-approves-vabysmo-to-treat-two-vision-threatening-retinal-conditions</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037533</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037533</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Mon, 31 Jan 2022 07:42:18 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Sun, 30 Jan 2022 17:00:37 GMT]]></title><description><![CDATA[<p dir="auto">Better Dividend Stock: AbbVie or Pfizer? <a href="https://www.proinvestor.com/investornyt/773458/better-dividend-stock-abbvie-or-pfizer" rel="nofollow ugc">https://www.proinvestor.com/investornyt/773458/better-dividend-stock-abbvie-or-pfizer</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037535</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037535</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Sun, 30 Jan 2022 17:00:37 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Sun, 16 Jan 2022 16:33:27 GMT]]></title><description><![CDATA[<p dir="auto">3 Pharma Stocks With Especially Juicy Dividends <a href="https://www.proinvestor.com/investornyt/765981/3-pharma-stocks-with-especially-juicy-dividends" rel="nofollow ugc">https://www.proinvestor.com/investornyt/765981/3-pharma-stocks-with-especially-juicy-dividends</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037530</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037530</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Sun, 16 Jan 2022 16:33:27 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Sat, 15 Jan 2022 11:54:19 GMT]]></title><description><![CDATA[<p dir="auto">Why This Under-the-Radar Healthcare Stock Could Be a Big Winner <a href="https://www.proinvestor.com/investornyt/765601/why-this-under-the-radar-healthcare-stock-could-be-a-big-winner" rel="nofollow ugc">https://www.proinvestor.com/investornyt/765601/why-this-under-the-radar-healthcare-stock-could-be-a-big-winner</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037531</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037531</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Sat, 15 Jan 2022 11:54:19 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Thu, 13 Jan 2022 05:18:44 GMT]]></title><description><![CDATA[<p dir="auto">Teva: Kåre Schultz giver klar melding på konference <a href="https://www.proinvestor.com/index.php?p=debat_1&amp;postid=100114" rel="nofollow ugc">https://www.proinvestor.com/index.php?p=debat_1&amp;postid=100114</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037534</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037534</guid><dc:creator><![CDATA[Helge_LarsenPI-redaktør]]></dc:creator><pubDate>Thu, 13 Jan 2022 05:18:44 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Wed, 12 Jan 2022 08:16:05 GMT]]></title><description><![CDATA[<p dir="auto">Here's A Better Pharmaceutical Pick Over Merck Stock <a href="https://www.proinvestor.com/investornyt/763435/heres-a-better-pharmaceutical-pick-over-merck-stock" rel="nofollow ugc">https://www.proinvestor.com/investornyt/763435/heres-a-better-pharmaceutical-pick-over-merck-stock</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037532</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037532</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Wed, 12 Jan 2022 08:16:05 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Sun, 09 Jan 2022 11:32:28 GMT]]></title><description><![CDATA[<p dir="auto">3 Big FDA Approvals to Watch For in Q1 2022 <a href="https://www.proinvestor.com/investornyt/761636/3-big-fda-approvals-to-watch-for-in-q1-2022" rel="nofollow ugc">https://www.proinvestor.com/investornyt/761636/3-big-fda-approvals-to-watch-for-in-q1-2022</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037526</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037526</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Sun, 09 Jan 2022 11:32:28 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Sat, 08 Jan 2022 16:51:22 GMT]]></title><description><![CDATA[<p dir="auto">3 Top Healthcare Stocks to Buy for January <a href="https://www.proinvestor.com/investornyt/761425/3-top-healthcare-stocks-to-buy-for-january" rel="nofollow ugc">https://www.proinvestor.com/investornyt/761425/3-top-healthcare-stocks-to-buy-for-january</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037528</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037528</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Sat, 08 Jan 2022 16:51:22 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Thu, 06 Jan 2022 12:40:22 GMT]]></title><description><![CDATA[<p dir="auto">Lundbeck får udvidet godkendelse af Rexulti i USA til brug i unge <a href="https://www.proinvestor.com/investornyt/760033/lundbeck-far-udvidet-godkendelse-af-rexulti-i-usa-til-brug-i-unge" rel="nofollow ugc">https://www.proinvestor.com/investornyt/760033/lundbeck-far-udvidet-godkendelse-af-rexulti-i-usa-til-brug-i-unge</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037537</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037537</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Thu, 06 Jan 2022 12:40:22 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Tue, 04 Jan 2022 12:25:39 GMT]]></title><description><![CDATA[<p dir="auto">Novo og sundhedsaktier ramt af genåbningshåb vurderer strateg <a href="https://www.proinvestor.com/investornyt/758638/novo-og-sundhedsaktier-ramt-af-genabningshab-vurderer-strateg" rel="nofollow ugc">https://www.proinvestor.com/investornyt/758638/novo-og-sundhedsaktier-ramt-af-genabningshab-vurderer-strateg</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037527</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037527</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Tue, 04 Jan 2022 12:25:39 GMT</pubDate></item><item><title><![CDATA[Reply to Pharma — Januar 2022 on Mon, 03 Jan 2022 12:15:50 GMT]]></title><description><![CDATA[<p dir="auto">Bioporto på himmelfart efter forlænget undersøgelse af covid-19-test <a href="https://proinvestor.com/investornyt/758103/bioporto-pa-himmelfart-efter-forlaenget-undersogelse-af-covid-19-test" rel="nofollow ugc">https://proinvestor.com/investornyt/758103/bioporto-pa-himmelfart-efter-forlaenget-undersogelse-af-covid-19-test</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8037529</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8037529</guid><dc:creator><![CDATA[ProinvestorNEWS]]></dc:creator><pubDate>Mon, 03 Jan 2022 12:15:50 GMT</pubDate></item></channel></rss>